moderate potency against human MGAT2, was inactive vs mouse MGAT2 and had poor microsomal metabolic stability. A novel chemistry route was developed to synthesize aryl dihydropyridinone analogs to explore structure–activity relationship around this hit, leading to the discovery of potent and selective MGAT2 inhibitors 21f, 21s, and 28e that are stable to liver microsomal metabolism. After triaging out 21f
MGAT2抑制是治疗代谢紊乱的潜在治疗方法。BMS 内部化合物集合的高通量筛选将芳基
二氢吡啶酮化合物1 (hMGAT2 IC 50 = 175 nM) 确定为命中。化合物1对人 MGAT2 具有中等效力,与小鼠 MGAT2 相比无活性,并且微粒体代谢稳定性差。开发了一种新的
化学路线来合成芳基
二氢吡啶酮类似物,以探索围绕这一命中的构效关系,从而发现对肝微粒体代谢稳定的有效和选择性 MGAT2
抑制剂21f、21s和28e。筛选出21f后由于其在体内效力、药代动力学和基于结构的责任和
四唑28e由于其较差的通道责任概况,21s (BMS-963272) 在饮食中证明了目标减肥功效后被选为临床候选者-诱导的肥胖小鼠模型和在多个临床前物种中可接受的安全性和耐受性特征。